However, the present study suggests that HD patients with low TRACP-5b/iPTH ratios are representative of those with bone resistance (decreased bone responsiveness) to PTH, probably associated with severe SHPT, which requires treatment with CaSR agonists and/or VDRAs, as reported by Díaz-Tocados et al. [27]. The gene discussed is CASR; the disease is Huntington disease.